Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931921 | 1.00 | AR (0.40) | AR | |
| SCHEMBL13206677 | 0.74 | AR (0.40) | AR | |
| SCHEMBL2516785 | 0.74 | AR (0.40) | AR | |
| SCHEMBL18884515 | 0.72 | AR (0.39) | AR | |
| SCHEMBL4821607 | 0.71 | AR (0.40) | AR | |
| SCHEMBL2754867 | 0.71 | AR (0.37) | AR | |
| SCHEMBL4818773 | 0.70 | AR (0.41) | AR | |
| SCHEMBL7558920 | 0.69 | CTSV (0.41) | AR | |
| SCHEMBL22356283 | 0.69 | AR (0.40) | AR | |
| SCHEMBL384647 | 0.69 | AR (0.40) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042850-A1 | PHARMACEUTICAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | ATHOS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2022159980-A1 | PHARMACEUTICAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | ATHOS THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-8168617-B2 | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-7994218-B2 | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use | XENOPORT, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033069-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1147101-B1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2002-11-20 | — | — | EP | disclosed |
| EP-1147101-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044739-A1 | REVERSE HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | AR 2331/4885 |
| US-20250042850-A1 | PHARMACEUTICAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PTGES, PTGIS, HPGDS | AR 1632/4885 |
| US-20090082440-A1 | SIMPLE PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | AR 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.